N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 22 NOK -2.22%
Market Cap: 527.6m NOK

Relative Value

The Relative Value of one NAVA stock under the Base Case scenario is hidden NOK. Compared to the current market price of 22 NOK, Navamedic ASA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAVA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
76
Median 3Y
1.1
Median 5Y
1.4
Industry
2.7
Forward
0.9
vs History
vs Industry
0
Median 3Y
-11.8
Median 5Y
-11.8
Industry
21.6
Forward
-38.5
vs History
41
vs Industry
37
Median 3Y
33.5
Median 5Y
33.5
Industry
16.9
vs History
20
vs Industry
29
Median 3Y
8.9
Median 5Y
8.8
Industry
22.9
vs History
57
vs Industry
45
Median 3Y
2.6
Median 5Y
2.6
Industry
2.3
vs History
57
vs Industry
76
Median 3Y
1.4
Median 5Y
1.4
Industry
3
Forward
1.3
vs History
41
vs Industry
70
Median 3Y
3.4
Median 5Y
3.7
Industry
5.6
vs History
7
vs Industry
27
Median 3Y
12.5
Median 5Y
14.5
Industry
13.4
Forward
14.7
vs History
12
vs Industry
32
Median 3Y
17.6
Median 5Y
18.1
Industry
16.7
Forward
40.8
vs History
41
vs Industry
36
Median 3Y
32.3
Median 5Y
32.3
Industry
16.1
vs History
26
vs Industry
30
Median 3Y
17
Median 5Y
15.5
Industry
18.9
vs History
77
vs Industry
54
Median 3Y
1.4
Median 5Y
1.8
Industry
2

Multiples Across Competitors

NAVA Competitors Multiples
Navamedic ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Navamedic ASA
OSE:NAVA
527.6m NOK 1 -13.4 92.8 92.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.5B CHF 4.4 28.8 12.3 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.9 159.4
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.4B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.4 11.4 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
NO
N
Navamedic ASA
OSE:NAVA
Average P/E: 24.9
Negative Multiple: -13.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBITDA: 408.4
92.8
17%
5.5
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 720.8
92.8
30%
3.1
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5